결합 백신 시장 : 유형별, 적응증별, 병원체 유형별, 최종사용자별 - 세계 예측(2025-2030년)

The Conjugate Vaccine Market was valued at USD 39.67 billion in 2023, expected to reach USD 43.92 billion in 2024, and is projected to grow at a CAGR of 10.81%, to USD 81.42 billion by 2030.

Conjugate vaccines are critical in preventing invasive diseases like meningitis, pneumonia, and Haemophilus influenzae type b (Hib) by linking polysaccharide antigens to protein carriers, enhancing immunogenicity, especially in young children. Their necessity stems from their ability to generate long-lasting immune responses and herd immunity, reducing disease incidence. Applications mainly include immunization programs targeting infants, young children, and adults with higher susceptibility to certain infectious diseases. End-use scope encompasses hospitals, clinics, public health agencies, and research institutions. Key growth influencers include heightened awareness of vaccine-preventable diseases, government immunization initiatives, and technological advancements in vaccine development. The market is buoyed by persistent investments in healthcare infrastructure and rising demand for pediatric vaccines due to stricter healthcare policies. The COVID-19 pandemic has also underscored the significance of vaccines, broadening the overall market focus on preventive healthcare. Emerging opportunities lie in geographical regions with low immunization coverage, highlighting the potential for expanding market footprints. Strategic collaborations in research and development sectors can propel technological innovations, maximizing market access. However, limitations such as vaccine hesitancy, supply chain disruptions, and high costs of vaccine development could impede growth. Stringent regulatory landscapes requiring extensive clinical evaluations pose additional challenges. Innovation can thrive in the development of thermostable vaccines, novel adjuvant systems, and combination vaccines that address multiple pathogens simultaneously. Exploring new mechanisms of conjugation and alternative carrier proteins can enhance efficacy and broaden protective scope. The nature of the conjugate vaccine market remains highly competitive, with a focus on partnerships between biotech firms, global health bodies, and governmental agencies to expand vaccine accessibility. By leveraging cutting-edge technologies like AI and machine learning in vaccine design, companies can optimize vaccine efficiency and target new pathogenic challenges, positioning themselves as leaders in the field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Conjugate Vaccine Market

The Conjugate Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of infectious diseases and immunosuppression
  • Rising adoption of cancer therapeutic vaccines
  • Rising number programs to promote vaccination by WHO
• Market Restraints
  • Low accessibility to vaccines in remote areas
• Market Opportunities
  • Government initiatives spreading awareness about infectious diseases
  • Advancement in technology for producing novel conjugate vaccines
• Market Challenges
  • Complexity of production procedure of conjugate vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Conjugate Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Conjugate Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Conjugate Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Conjugate Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Conjugate Vaccine Market

A detailed market share analysis in the Conjugate Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Conjugate Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Conjugate Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Conjugate Vaccine Market

A strategic analysis of the Conjugate Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Conjugate Vaccine Market, highlighting leading vendors and their innovative profiles. These include Bavarian Nordic, Bharat Biotech Ltd., Bio-Med Limited, Biological E. Limited, Biological E. Ltd, CSL Limited, GlaxoSmithKline, plc., Merck and Company, Novartis AG, Nuron Biotech Inc., Pfizer, Inc., Sanofi Pasteur U.S., LLC, Serum Institute of India Pvt. Ltd., Taj Pharmaceuticals Limited, and Vaxcyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Conjugate Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Monovalent and Multivalent.
• Based on Indication, market is studied across Diphtheria & Pertussis, Influenza, Meningococcal, and Pneumococcal.
• Based on Pathogen Type, market is studied across Bacterial Conjugate Vaccine, Combination Conjugate Vaccine, and Viral Conjugate Vaccine.
• Based on End-User, market is studied across Adults and Children.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of infectious diseases and immunosuppression
    • 5.1.1.2. Rising adoption of cancer therapeutic vaccines
    • 5.1.1.3. Rising number programs to promote vaccination by WHO
  • 5.1.2. Restraints
    • 5.1.2.1. Low accessibility to vaccines in remote areas
  • 5.1.3. Opportunities
    • 5.1.3.1. Government initiatives spreading awareness about infectious diseases
    • 5.1.3.2. Advancement in technology for producing novel conjugate vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity of production procedure of conjugate vaccine
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Conjugate Vaccine Market, by Type

• 6.1. Introduction
• 6.2. Monovalent
• 6.3. Multivalent

7. Conjugate Vaccine Market, by Indication

• 7.1. Introduction
• 7.2. Diphtheria & Pertussis
• 7.3. Influenza
• 7.4. Meningococcal
• 7.5. Pneumococcal

8. Conjugate Vaccine Market, by Pathogen Type

• 8.1. Introduction
• 8.2. Bacterial Conjugate Vaccine
• 8.3. Combination Conjugate Vaccine
• 8.4. Viral Conjugate Vaccine

9. Conjugate Vaccine Market, by End-User

• 9.1. Introduction
• 9.2. Adults
• 9.3. Children

10. Americas Conjugate Vaccine Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Conjugate Vaccine Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Conjugate Vaccine Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bavarian Nordic
• 2. Bharat Biotech Ltd.
• 3. Bio-Med Limited
• 4. Biological E. Limited
• 5. Biological E. Ltd
• 6. CSL Limited
• 7. GlaxoSmithKline, plc.
• 8. Merck and Company
• 9. Novartis AG
• 10. Nuron Biotech Inc.
• 11. Pfizer, Inc.
• 12. Sanofi Pasteur U.S., LLC
• 13. Serum Institute of India Pvt. Ltd.
• 14. Taj Pharmaceuticals Limited
• 15. Vaxcyte, Inc.